vTv Therapeutics Stock (NASDAQ:VTVT)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$14.52

52W Range

$7.38 - $30.99

50D Avg

$14.99

200D Avg

$18.63

Market Cap

$39.08M

Avg Vol (3M)

$30.00K

Beta

0.63

Div Yield

-

VTVT Company Profile


vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Jul 30, 2015

Website

VTVT Performance


VTVT Financial Summary


Dec 23Dec 22Dec 21
Revenue-$2.02M$4.00M
Operating Income$-25.50M$-22.54M$-21.66M
Net Income$-20.25M$-25.07M$-17.73M
EBITDA$-25.41M$-24.86M$-17.60M
Basic EPS$-9.71$-0.53$-0.29
Diluted EPS$-9.71$-0.53$-0.29

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ERASErasca, Inc.
PHIOPhio Pharmaceuticals Corp.
GBIOGeneration Bio Co.
KRONKronos Bio, Inc.
GOVXGeoVax Labs, Inc.
INMInMed Pharmaceuticals Inc.
EWTXEdgewise Therapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
CCCCC4 Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
ALLRAllarity Therapeutics, Inc.
CYTOAltamira Therapeutics Ltd.
NRBONeuroBo Pharmaceuticals, Inc.
PYXSPyxis Oncology, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.